This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Pridinol is an atropine-like muscle relaxant indicated in the treatment of muscle pain associated with muscle tightness.
- Generic Name
- Pridinol
- DrugBank Accession Number
- DB13642
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Pridinol (DB13642)
- Weight
- Average: 295.426
Monoisotopic: 295.193614429 - Chemical Formula
- C20H25NO
- Synonyms
- Pridinol
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Soreness, muscle •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Pridinol. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Pridinol. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Pridinol. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Pridinol. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Pridinol. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Pridinol mesilate AQ4K0AJT6G 6856-31-1 VNJHUUNVDMYCRH-UHFFFAOYSA-N
Categories
- ATC Codes
- M03BX03 — Pridinol
- M03BX — Other centrally acting agents
- M03B — MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
- M03 — MUSCLE RELAXANTS
- M — MUSCULO-SKELETAL SYSTEM
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Aralkylamines / Piperidines / Tertiary alcohols / 1,3-aminoalcohols / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- 1,3-aminoalcohol / Alcohol / Amine / Aralkylamine / Aromatic alcohol / Aromatic heteromonocyclic compound / Azacycle / Diphenylmethane / Hydrocarbon derivative / Organic nitrogen compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- piperidines, tertiary alcohol (CHEBI:75247)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9E75Q6SUUB
- CAS number
- 511-45-5
- InChI Key
- RQXCLMGKHJWMOA-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H25NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1-2,4-7,10-13,22H,3,8-9,14-17H2
- IUPAC Name
- 1,1-diphenyl-3-(piperidin-1-yl)propan-1-ol
- SMILES
- OC(CCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
References
- General References
- AIFA Product Information: Lyseen (pridinol) for oral use [Link]
- External Links
- ChemSpider
- 4735
- 34479
- ChEBI
- 75247
- ChEMBL
- CHEMBL404215
- ZINC
- ZINC000001482149
- Wikipedia
- Pridinol
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Injection, solution Intramuscular; Intravenous Injection, solution Intramuscular; Intravenous 2 MG/ML Suppository 6 MG Tablet Oral 4 MG Tablet Oral Tablet Oral 3.02 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0192 mg/mL ALOGPS logP 3.69 ALOGPS logP 3.7 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 13.36 Chemaxon pKa (Strongest Basic) 9.34 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 23.47 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 92.27 m3·mol-1 Chemaxon Polarizability 34.68 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-2090000000-fbf86bd99173e91c9983 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-0090000000-e240cc509e4a48ee0c3f Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-002b-4590000000-02194944a07083d87978 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-1960000000-e93e28ee89f4ce400793 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00kb-4940000000-f95f6563e5aa4a20bf3d Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-0900000000-10cf6b82915cab0cd208 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 183.3265192 predictedDarkChem Lite v0.1.0 [M-H]- 168.02255 predictedDeepCCS 1.0 (2019) [M+H]+ 183.3495192 predictedDarkChem Lite v0.1.0 [M+H]+ 170.38055 predictedDeepCCS 1.0 (2019) [M+Na]+ 182.9969192 predictedDarkChem Lite v0.1.0 [M+Na]+ 176.4737 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:45 / Updated at May 29, 2021 18:12